RNDO-Program2

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameRNDO-Program2
Drug Alias NameRNDO-Program2
ClassificationBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsT-cell-specific surface glycoprotein CD28 modulators
TargetsT cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRondo Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRondo Therapeutics
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A